Hints and tips:
...It was unbelievable,” said Alisha Alaimo, Biogen’s North America head....
...In the UK, Eisai submitted the drug for approval in May....
...That is why the design of the trial . . . is so important,” Ivan Cheung, US chief executive of Eisai, said in an interview....
...Already 60 per cent of new annual cases are in Asia, Africa and Latin America, according to the WHO....
...Hanes and DBA were formerly sister companies under the ownership of Sara Lee Corporation....
...Domestic sales at Japan’s five biggest pharmaceuticals groups – Takeda, Astellas Pharma, Daiichi Sankyo, Eisai and Chugai Pharmaceutical – account for between 45 and 90 per cent of revenues....
...It is currently testing expanded use of its injectable treatment Victoza for weight loss. Japanese companies have proved more active: Eisai partnered with Arena and Takeda with Orexigen....
...“Company”) and its subsidiaries (”the AorTech Group”) is an agreement (the “Agreement”) for the license and supply of AorTech’s proprietary materials to Pacesetter Inc. dba St....
...Eisai, the Japanese drugmaker, is to refocus its business on East Asia, in a sign of renewed confidence in the region that breaks with the more global ambitions of its peers....
...Camera maker Konica Minolta rose 1.2 per cent to Y608 on reports its first-quarter operating profit was expected to rise about 70 per cent from a year earlier on higher sales in North America, China and...
...Prof Hotez has long highlighted the burden of NTDs, such as helminths and leishmaniasis, in the poor rural and indigenous communities of North America....
...Schincariol is not Japan Inc’s first brush with tough acquisitions....
...Companies are shifting clinical trials, among the most costly parts of drug development, into eastern Europe, Latin America and Asia....
...The Ireland-based drugmaker divested the product in 2004, selling it to the Japanese group Eisai for $130m, with the potential for further earnings of $110m on the sale....
...government to retain their control of HIV drugs a decade ago....
...Eisai, a big drugmaker, paid its American senior vice-president, Lonnel Coats, Y140m, Y4m more than its Japanese president and chief executive Haruo Naito....
.... $4bn is 9.3 times last year’s revenues – much cheaper than the CV bid (12 times), Eisai/MGI Pharma (13.5) and Takeda/Millennium (16.7)....
...will be in wide-girthed America and Europe....
...Takeda Pharmaceutical, which is Asia’s biggest drugmaker and receives 41 per cent of sales in North America, added 1.7 per cent to Y40.00....
...In 2007, Eisai, Japan’s fourth-largest drugsmaker, bought MGI Pharma of the US for $3.9bn....
...Patents on Takeda’s diabetes drug Actos and its stomach medication Prevacid expire during the next couple of years. For Eisai, its Aricept patent – an Alzheimer’s drug – expires in 2010....
...Eisai led the Nikkei lower with a 6 per cent decline to Y2,685, while Astellas followed with a 5.3 per cent decline to Y2,860....
...Last December Eisai said it would buy MGI Pharma, a US biotech group, for $3.9bn....
...In December, Eisai said it would acquire MGI Pharma, a US biotech group, for $3.9bn....
...Defensive stocks remained in play, helping limit declines on the Nikkei, with Fast Retailing, the maker of the Uniqlo brand, gaining 1.9 per cent to Y13,770, and pharmaceutical companies Astellas and Eisai...
International Edition